Product News
Filter News
Found 274,469 articles
-
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
4/23/2024
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.
-
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
4/23/2024
ImmunityBio, Inc., an immunotherapy company, announced that the U.S. Food and Drug Administration has approved ANKTIVA plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
-
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes
4/23/2024
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes.
-
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
4/23/2024
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™.
-
Screening Completed: Berlin Cures Achieves Key Milestone in BC 007 Phase II Trial for Treatment of Long COVID
4/23/2024
Berlin Cures announced the successful completion of patient screening for its pan-European Phase II trial of BC 007, a novel therapeutic candidate for the treatment of Long COVID.
-
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
4/22/2024
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET.
-
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
4/22/2024
Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 Inhibitor Suitable for Clinical Assessment”.
-
Zydus launches Mirabegron Extended-Release Tablets in the US
4/22/2024
Zydus Lifesciences Limited announces the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market.
-
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
4/22/2024
Oryzon Genomics, S.A. announced that the European Patent Office has issued an “intention to grant” communication for Oryzon’s European patent application EP18748921.6 entitled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.
-
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
4/22/2024
Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.
-
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
4/22/2024
NovaBay® Pharmaceuticals, Inc. announces a new and enhanced marketing program that includes text message communications and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products.
-
Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns
4/22/2024
Waters Corporation introduced new GTxResolve Premier Size Exclusion Chromatography 1000Å 3-micron Columns.
-
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
4/22/2024
Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.
-
Molecular You Announces Breakthrough in Early Detection of Pancreatic Cancer
4/22/2024
Molecular You has achieved a significant milestone in the early detection of pancreatic cancer.
-
First Ascent Biomedical’s New Study Shows Functional Precision Medicine Platform Identifies Effective Treatments for 83 Percent of Children with Difficult-to-Treat Cancers
4/22/2024
First Ascent Biomedical announced today results from a prospective clinical study conducted in partnership with Florida International University (FIU) using a unique and groundbreaking functional precision medicine (FPM) platform.
-
Exactech Strengthens Position as Soft Tissue Balancing Technology Leader with New Patents
4/22/2024
Exactech announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent #11,944,365 and #11,950,820, fortifying the company's intellectual property and protection around its novel Newton® soft tissue balancing technology for total knee replacement surgery.
-
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
4/22/2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder.
-
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
4/22/2024
Adial Pharmaceuticals, Inc. today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.
-
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
4/22/2024
NeuroSense Therapeutics Ltd. announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+ , a leader in precision medicine for psychiatry and neurology.
-
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
4/22/2024
Guardant Health, Inc. today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.